Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125488192 | 12548819 | 2 | F | 20160525 | 20160802 | 20160712 | 20160808 | EXP | FR-AFSSAPS-CN20160423 | FR-GLAXOSMITHKLINE-FR2016GSK094341 | GLAXOSMITHKLINE | 77.62 | YR | M | Y | 0.00000 | 20160808 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125488192 | 12548819 | 1 | PS | Zelitrex | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | UNK | Y | 20487 | |||||||||
| 125488192 | 12548819 | 2 | SS | Zelitrex | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | UNK | Y | 20487 | |||||||||
| 125488192 | 12548819 | 3 | SS | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | 200 MG, QD | Y | 0 | 200 | MG | QD | ||||||
| 125488192 | 12548819 | 4 | SS | PRIMPERAN | METOCLOPRAMIDE HYDROCHLORIDE | 1 | Oral | 10 MG, PRN | Y | 0 | 10 | MG | |||||||
| 125488192 | 12548819 | 5 | SS | Flecaine | FLECAINIDE | 1 | Oral | 150 MG, 1D | 0 | 150 | MG | QD | |||||||
| 125488192 | 12548819 | 6 | SS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | UNK | Y | 0 | 375 | MG/M**2 | |||||||
| 125488192 | 12548819 | 7 | SS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | SECOND COURSE OF RITUXIMAB (1 INJECTION OF 500 MG/M2 MONTHLY | Y | 0 | 500 | MG/M**2 | |||||||
| 125488192 | 12548819 | 8 | SS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | THIRD COURSE OF RITUXIMAB (1 INJECTION OF 500 MG/M2 MONTHLY | Y | 0 | 500 | MG/M**2 | |||||||
| 125488192 | 12548819 | 9 | SS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 1 INJECTION OF 500 MG/M2 MONTHLY | Y | 0 | 500 | MG/M**2 | |||||||
| 125488192 | 12548819 | 10 | SS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | FIFTH COURSE OF RITUXIMAB | Y | 0 | 500 | MG/M**2 | |||||||
| 125488192 | 12548819 | 11 | SS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 500 MG/M2, UNK | Y | 0 | 500 | MG/M**2 | |||||||
| 125488192 | 12548819 | 12 | SS | XARELTO | RIVAROXABAN | 1 | Oral | 15 MG, UNK | Y | 0 | 15 | MG | |||||||
| 125488192 | 12548819 | 13 | SS | ZYDELIG | IDELALISIB | 1 | Oral | 150 MG, Z | Y | 0 | 150 | MG | |||||||
| 125488192 | 12548819 | 14 | SS | ZYDELIG | IDELALISIB | 1 | Oral | 150 MG, BID | Y | 0 | 150 | MG | BID | ||||||
| 125488192 | 12548819 | 15 | SS | ZYDELIG | IDELALISIB | 1 | Oral | 150 MG, BID | Y | 0 | 150 | MG | BID | ||||||
| 125488192 | 12548819 | 16 | SS | ZYDELIG | IDELALISIB | 1 | Oral | 150 MG, BID | Y | 0 | 150 | MG | BID | ||||||
| 125488192 | 12548819 | 17 | SS | ZYDELIG | IDELALISIB | 1 | Oral | 150 MG, BID | Y | 0 | 150 | MG | BID | ||||||
| 125488192 | 12548819 | 18 | C | BISOPROLOL | BISOPROLOL | 1 | U | 0 | |||||||||||
| 125488192 | 12548819 | 19 | C | Lercanidipine | LERCANIDIPINE | 1 | 0 | ||||||||||||
| 125488192 | 12548819 | 20 | C | Atorvastatin | ATORVASTATIN | 1 | UNK | 0 | |||||||||||
| 125488192 | 12548819 | 21 | C | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | 1 UNK, Z | 0 | 1 | DF |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125488192 | 12548819 | 1 | Prophylaxis |
| 125488192 | 12548819 | 3 | Product used for unknown indication |
| 125488192 | 12548819 | 4 | Nausea |
| 125488192 | 12548819 | 5 | Transient ischaemic attack |
| 125488192 | 12548819 | 6 | Lymphoma |
| 125488192 | 12548819 | 12 | Transient ischaemic attack |
| 125488192 | 12548819 | 13 | Lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125488192 | 12548819 | HO |
| 125488192 | 12548819 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125488192 | 12548819 | Dermatitis exfoliative |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125488192 | 12548819 | 1 | 201601 | 20160525 | 0 | |
| 125488192 | 12548819 | 2 | 201601 | 20160525 | 0 | |
| 125488192 | 12548819 | 3 | 201601 | 20160525 | 0 | |
| 125488192 | 12548819 | 4 | 201601 | 20160525 | 0 | |
| 125488192 | 12548819 | 5 | 20160104 | 0 | ||
| 125488192 | 12548819 | 6 | 20160104 | 20160525 | 0 | |
| 125488192 | 12548819 | 7 | 20160201 | 0 | ||
| 125488192 | 12548819 | 8 | 20160301 | 0 | ||
| 125488192 | 12548819 | 9 | 20160330 | 0 | ||
| 125488192 | 12548819 | 10 | 20160427 | 0 | ||
| 125488192 | 12548819 | 11 | 20160525 | 0 | ||
| 125488192 | 12548819 | 12 | 20160104 | 2016 | 0 | |
| 125488192 | 12548819 | 13 | 20160104 | 20160525 | 0 | |
| 125488192 | 12548819 | 14 | 20160301 | 0 | ||
| 125488192 | 12548819 | 15 | 20160330 | 0 | ||
| 125488192 | 12548819 | 16 | 20160427 | 0 | ||
| 125488192 | 12548819 | 17 | 20160525 | 0 | ||
| 125488192 | 12548819 | 20 | 20160525 | 0 | ||
| 125488192 | 12548819 | 21 | 201601 | 20160120 | 0 |